Navigating expanded access in Europe: a strategic blueprint for biotech leaders
An in-depth exploration on strategizing Early Access Programs in Europe
Good clinical trial data, increased patient and clinician understanding of treatment options and the rise of powerful patient advocacy groups are all driving demand for access to unlicensed medications. This presents a dilemma for pharma companies, who desperately want to be able to support patients they know could benefit from access to their product.
Download this guide to learn more about the benefits and challenges of planning and launching a European access program and the key factors US biotechs must consider at the beginning of their access program journey, including:
- The different types of access programs
- The benefits and challenges for US biotechs
- Patient expectations
- Important factors to consider.